Continuing Medical Education: November 2016 Instructions

Statement of educational need

Current treatment options for inflammatory bowel disease (IBD) include 5-aminosalicates, corticosteroids, immunomodulatory therapy, biologic therapy and surgery. Treatment is traditionally a step wise progression, however to-date the main clinical consideration has been when to ‘step up’. Newer therapies available for IBD offer ‘choices’ at several steps of the treatment algorithm. In addition, clinical and biochemical markers of prognosis and response to therapy are becoming increasingly relevant to better characterize prognosis and assess response. This supplement reviews the emerging opportunities for a more patient-centered individualized approach to management and makes some expert opinion recommendations on the choices now available to physicians.

Target audience

This activity has been designed to meet the educational needs of gastroenterologists and other physician involved in the care of patients with inflammatory bowel disease (IBD). Other healthcare providers may also find this content of interest.

Media

Print supplement.

Accreditation statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Estimated time to completion

3 hours plus 30 minutes to complete the post-activity evaluation and post-test.

Date of expiration

Valid for credits through December 31st, 2017.

Learning objectives

After completing this activity, the participant should be better able to:

- Summarize established management paradigms for IBD, including areas of unmet clinical needs
- Stratify patients according to probable disease and therapeutic outcomes based on current clinical evidence, biochemical, and serologic markers
- Evaluate the mechanisms of action of novel therapies for IBD and how they differ from existing agents and relate to the pathophysiology of IBD
- Compare the efficacy and safety of therapies available for patients with IBD
- Identify how to integrate novel therapies into a wider management paradigms
- Select appropriate individualized management options for patients with UC and CD

Method of participation and request for credit

For your convenience the post-activity test is reproduced in this supplement. To request credit, please go online to CME University at: www.cmeuniversity.com, and register or login (takes less than 1 minute). Once logged in, follow these steps:

- Click on the “Find Post-Test/Evaluation by Course:” at the top of the page.
- Type in “10541” and hit enter.
- Click on the activity title when it appears.
- Choose your profession/type of credit you are seeking.
- Complete the online posttest with a passing score of 75% or better and the online evaluation.

Upon successful completion of the posttest and evaluation form, you will have immediate access to a certificate of attendance to print or save for your files.

If you have any questions regarding the CE certification for this activity, please contact Postgraduate Institute for Medicine at: information@pimed.com or (303) 799-1930.

Commercial support

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region.

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
<table>
<thead>
<tr>
<th>Name of Faculty or Presenter</th>
<th>Reported Financial Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>David T. Rubin, MD</td>
<td>Consultant: AbbVie, Amgen, Emmi, Genentech, Janssen, Pfizer, Prometheus Laboratories, Santarus/Salix, Shire, Takeda, Telstar Pharmaceuticals, UCB Pharma. Grant support: AbbVie, Genentech, Janssen, Prometheus Laboratories, Shire, Takeda, UCB Pharma. Ownership: Cornerstone Health. Other: ACG (Board of Trustees).</td>
</tr>
<tr>
<td>Julia Greer MD, MPH</td>
<td>Grant (institutional): AbbVie.</td>
</tr>
<tr>
<td>Dermot P.B. McGovern, MD, PhD, MRCP (UK)</td>
<td>Consulting: Janssen, Merck, UCB Pharma.</td>
</tr>
<tr>
<td>Miguel D. Regueiro, MD</td>
<td>Consulting: AbbVie, Janssen, Shire, Takeda, UCB Pharma.</td>
</tr>
<tr>
<td>Scott B. Snapper, MD, PhD</td>
<td>Consulting: Enterome, Hoffman-La Roche, Janssen, Merck, Pfizer, Synlogic.</td>
</tr>
</tbody>
</table>

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following SCI planners and managers, Ian Morgan, MSc, and Elena Urso, BSc, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity or any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.